Drug major Cipla today said its JV firm Stempeutics Research has received process patent from the Japan Patent Office for novel stem cell drug Stempeucel aimed at treatment of critical limb ischemia (CLI).
Stempeutics chief operating officer B N Manohar said: "The new patent strengthens our position in Japan, which have created an accelerated development path for stem cell therapies."
The company is actively evaluating the potential for accelerated development of Stempeucel product for CLI and Osteoarthritis indications in Japan with strategic collaborations, he added.
CLI is a severe obstruction of the arteries, which markedly reduces blood flow to the extremities (hands, feet and legs).
"Japan is showing great leadership in innovating a regulatory framework for regenerative medicine thereby addressing major unmet medical needs faster," Cipla New Ventures Head Chandru Chawla said.
Shares of Cipla were trading at Rs 617.50 per scrip in the afternoon trade on BSE, down 0.99 per cent.
